HHS launches web-based locator for COVID-19 outpatient treatment sites for monoclonal antibodies

HHS has unveiled a web-based COVID-19 outpatient treatment locator to help patients and health care providers find potential locations for treatment with monoclonal antibody therapeutics.

HHS has unveiled a web-based COVID-19 outpatient treatment locator to help patients and health care providers find potential locations for treatment with monoclonal antibody therapeutics. Robert Kadlec, MD, the HHS Assistant Secretary for Preparedness and Response, said: "We know that many hospitals are overwhelmed with the recent rise in patients hospitalized with COVID-19, and hospital staff are exhausted after months of pandemic response. This treatment locator allows patients and providers to find sites for outpatient treatment options, which may help reduce the number of people who require hospitalization for COIVD-19 care, which in turn reduces the strain on our nation's hospitals and their staff." HHS has agreements in place with Regeneron to purchase approximately 300,000 treatment courses of the company's casirivimab/imdevimab and with Eli Lilly to buy about 3 million treatment courses of the bamlanivimab, if needed. As of January 6, HHS had allocated more than 641,000 patient treatment courses to states and territories, which then directed delivery of the medicines to more than 3,700 locations. About three-quarters of the treatment courses allocated thus far remain available for use in the authorized patient populations. The COVID-19 therapeutics distribution page lists locations where the monoclonal antibody therapeutics have been delivered, including the facility name and address and which monoclonal antibody therapeutic was delivered. The site only lists facilities that are open to the general public. States and territorial health departments must opt in to have information for facilities within their jurisdictions available in the treatment locator. Already, 22 state and territorial health departments have opted in.